TVGN — Tevogen Bio Holdings Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Tevogen Bio Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.62 | 13.7 | 8.84 | 61.1 | 26.1 |
| Operating Profit | -4.62 | -13.7 | -8.84 | -61.1 | -26.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.6 | -22 | -60.5 | -13.7 | -26.3 |
| Net Income After Taxes | -15.6 | -22 | -60.5 | -13.7 | -26.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.6 | -22 | -60.5 | -13.7 | -26.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.6 | -22 | -60.5 | -10.3 | -26.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.04 | -7.12 | -19.5 | -0.946 | -8.08 |
| Dividends per Share |